Market positioning VivaQuant specializes in quantitative ECG analysis for biomedical and drug safety research, presenting a clear value proposition for pharmaceutical, biotech, and contract research organizations seeking accurate, low-noise cardiac signal measurements to support arrhythmia liability assessment and regulatory submissions.

Technology edge Proprietary MDSP technology that eliminates 95% of noise while preserving signal fidelity positions VivaQuant as a premium analytics partner. This capability can be leveraged to upsell advanced ECG processing services and longer-term data analysis contracts with clients facing high artifact rates.

Product evolution A history of scalable products from RX-1 mini to AE-1010 Rhythm Express indicates a track record of productized ECG analysis solutions that can be deployed across studies, enabling cross-sell of software licenses and services to existing customers with expanding trial sizes and data volumes.

Growth signals Revenue range suggests a mid-market focus with potential for expansion through enlarging clinical programs, CRO partnerships, and pharmacovigilance programs. Engage prospects about integrated workflows, data warehousing, and regulatory-ready reporting to increase deal sizes.

Expansion opportunities Recent recognition in Tekne Awards and patent activity signals credibility and innovation leadership. Target large pharma and mid-sized biotech firms undergoing cardiovascular safety needs, offering joint development, licensing, or custom integration opportunities around MDSP-powered denoising and precise interval measurements.